医学
内科学
美罗华
套细胞淋巴瘤
奥比努图库单抗
胃肠病学
移植
淋巴瘤
外科
作者
Clémentine Sarkozy,Mary Callanan,Catherine Thiéblemont,Lucie Obéric,Barbara Burroni,Krimo Bouabdallah,Gandhi Damaj,Benoît Tessoulin,Vincent Ribrag,Roch Huout,Franck Morschhauser,Samuel Griolet,Clémentine Joubert,Victoria Cacheux,Vincent Delwail,Violaine Safar,Rémy Gressin,Morgane Cheminant,Marie‐Hélène Delfau‐Larue,Olivier Hermine,Elizabeth Macintyre,Steven Le Gouill
出处
期刊:Blood
[American Society of Hematology]
日期:2024-04-26
标识
DOI:10.1182/blood.2024023944
摘要
Obinutuzumab (O) and Rituximab (R) are two CD antibodies that have never been compared in a prospective randomised trial in mantle cell lymphoma (MCL). Herein, we report the long-term outcome of the LYMA-101 (NCT02896582) trial, in which newly diagnosed MCL patients were treated with chemotherapy plus O before transplantation followed by O maintenance (O group). We then compared these patients to those treated with the same treatment design with Rituximab instead of O (R group) (NCT00921414). A propensity score matching (PSM) was used to compare the two populations (O vs R groups) in terms of MRD at the end of induction (EOI), PFS and OS. In LYMA-101, the estimated five-year PFS and OS since inclusion (n=85) were 83.4% (95%CI: 73.5-89.8%) and 86.9% (95%CI: 77.6-92.5%), respectively. At EOI, patients treated in the O group had more frequent bone marrow MRD negativity than those treated in the R group (83.1% vs 63.4% Chi2 p=0.007). The PSM resulted in 2 sets of 82 patients with comparable characteristics at inclusion. From treatment initiation, the O group had a longer estimated five-year PFS (p=0.029; 82.8% versus 66.6%, HR 1.99, IC95 1.05-3.76) and OS (p=0.039; 86.4% versus 71.4% (HR 2.08, IC95 1.01-4.16) compared to the R group. Causes of death were comparable in the 2 groups, the most common cause being lymphoma. Obinutuzumab prior to transplantation and in maintenance provides better disease control and enhances PFS and OS, as compared to Rituximab in transplant-eligible MCL patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI